Paragon works with clients that are at the forefront of next generation therapeutics utilizing oncolytic viruses to improve current cancer therapies and practices.
Oncolytic viruses have tremendous therapeutic potential and will have a significant impact on public health. However, manufacturing constraints have become a bottle neck in the advancement of this technology. Our dedicated staff are uniquely skilled in solving these challenges and developing a scalable manufacturing process that can be the platform for commercial success. Leveraging our live-virus and VLP experiences as well as the latest manufacturing technologies (e.g. iCELLis fixed-bed bioreactors), Paragon expeditiously moves your oncolytic program forward for initial early-stage clinical evaluation while positioning for rapid progression to a late-stage and commercial setting.